Interestingly, both BCL-XL (BCL2L1) and BCL-w (BCL2L2) were identified as negative regulators of TRAIL-induced caspase-3/7 activation in the breast cancer cells by our primary screen. This evidence concerns the gene BCL2L2 and breast cancer.